Taipei Exchange Launches Dedicated Sustainable Bond Segment to Further Issuing Momentum
24.5.2021 12:00:00 EEST | Business Wire | Press release
The Taipei Exchange, TPEx, launched a dedicated segment for sustainable bonds, celebrating on May 18 with the debut of three social bond listings. The segment marks a milestone for Taiwan’s socially responsible investment and is in accordance with a plan announced by the Taiwanese government’s Financial Supervisory Commission (FSC). The commission’s plan, named the Green Finance Action Plan 2.0, was announced in August 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005043/en/
Taipei Exchange launches dedicated sustainable bond segment to further issuing momentum. (Graphic: Business Wire)
TPEx Chairman Philip Chen said in a statement announcing the new segment, “After accomplishing the mechanism regarding social bonds, the last piece of the puzzle, TPEx has integrated the regulations of Green Bonds, Sustainability Bonds, and Social Bonds and launched this segment exclusively for ESG concept bonds.” Chen went on to highlight TPEx’s market acclaim for launching Green Bond and Sustainability Bond operational directions in 2017 and 2020 respectively, which were in line with the ICMA’s GBP and SBG. The total outstanding amount of listed sustainable bonds has steadily grown, exceeding NT$207bn (US$7bn), according to Chen.
The first batch of three social bonds listed on TPEx is primarily funding socioeconomic advancement projects related to the global COVID-19 pandemic, projects such as increasing access to loans, providing job opportunities and raising the availability of affordable housing.
FSC Chairman Dr. Tien-Mu Huang said, “FSC fully supports financial innovation and product diversity. The Sustainable Bond Segment at TPEx provides the market with a clearer, more complete and consistent regulatory mechanism, facilitating easier compliance for issuers. This subsequently serves to direct funds to eco-friendly and socially beneficial projects, helping achieve the goals of Green Finance Action Plan 2.0 tremendously.” Mrs. Tania Berchem from the Luxemburg Trade and Investment Office in Taipei, Mr. Nicholas Pfaff from ICMA, and Mr. Sean Kidney from CBI all sent their congratulatory messages to TPEx for the dedicated segment.
Meanwhile, TPEx has modernized its sustainable bonds website (https://www.tpex.org.tw/web/bond/sustainability/index.php?l=en-us), improving all relevant information for clarity and accessibility. The updated website is bilingual, and key features have been added which include issuance status and bond framework information, assessment opinions from external reviewers, market reports, and access to current sustainability studies and research reports. Speaking of the new website, Chen added, “In facilitating responsible investing, we hope to offer a full array of information to enhance transparency while simultaneously raising investors’ social awareness.”
About the Taipei Exchange
Established in 1994, the Taipei Exchange is a member of the World Federation of Exchanges. The exchange has grown with a vision of sustainability to meet the diverse needs of issuers and investors, and has long been dedicated to fostering emerging, high-tech and creative industries by providing a viable channel for raising capital. The exchange has also established a fast-growing bond market. For more information, visit: https://www.tpex.org.tw/web/index.php?l=en-us
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005043/en/
Contact information
Tinna Chen: tinnachen@tpex.org.tw
Iris Yang: irisyang@tpex.org.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom